Selatogrel is a small molecule commercialized by Idorsia Pharmaceutical, with a leading Phase III program in Myocardial Infarction. According to Globaldata, it is involved in 10 clinical trials, of which 8 were completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Selatogrel’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Selatogrel is expected to reach an annual total of $509 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Selatogrel is under development for the treatment of acute myocardial infarction. The drug candidate is administered through subcutaneous route. It acts by targeting P2Y12 receptor. It is a new chemical entity (NCE).
It was also under development for the treatment of acute coronary syndrome.
Idorsia Pharmaceutical Overview
Idorsia Pharmaceutical (Idorsia) is a biopharmaceutical company that discovers, develops, and commercializes small molecules to treat the central nervous system and cardiovascular and immunological disorders. It is investigating daridorexant against insomnia; aprocitentan for the treatment of resistant hypertension; clazosentan to treat cerebral vasospasm associated with aneurysmal subarachnoid hemorrhage; and L-lucerastat compound targeting fabry disease. The company is also evaluating drugs against suspected acute myocardial infarction, systemic lupus erythematosus, Binge eating disorder and rare lysosomal storage disorders. It works in collaboration with Janssen Biotech to develop and commercialize aprocitentan drug candidates. Idorsia is headquartered in Allschwil, Switzerland.
The company reported revenues of (Swiss Francs) CHF97.1 million for the fiscal year ended December 2022 (FY2022), compared to a revenue of CHF35.4 million in FY2021. The operating loss of the company was CHF803 million in FY2022, compared to an operating loss of CHF613 million in FY2021. The net loss of the company was CHF827.9 million in FY2022, compared to a net loss of CHF634.6 million in FY2021. The company reported revenues of CHF21 million for the first quarter ended March 2023, a decrease of 60.9% over the previous quarter.
For a complete picture of Selatogrel’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.